BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Positron Corporation (POSC) Announces Strontium Sale


12/7/2012 9:37:58 AM

CHICAGO, Dec. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) posts their first commercial sale and shipment of Active Pharmaceutical Ingredient (API) grade Strontium-82 to a North American pharmaceutical company. Manhattan Isotope Technology (MIT), LLC, a wholly owned subsidiary of Position Corporation, completed the processing, production and shipment of their API grade strontium-82, which was delivered this week. The API was produced from target material received from one of its foreign collaborators for target irradiation.

Strontium-82, API, is used exclusively to manufacture rubidium-82 generators and is the most widely accepted Positron Emission Tomography (PET) agent utilized in myocardial perfusion imaging.

"I and my team at MIT, have been developing our isotope production business for many years. This API shipment is a culmination of our company's expertise, research & development efforts, dedication to our isotope program and the efficiencies of MIT's Sr-82 production facility," said Jason Kitten, President of MIT and Positron's Director of Radiopharmaceutical & Radioisotope Production. "Positron's commitment to Rb-82 based cardiac PET continues by addressing the single largest factor limiting its growth, Strontium-82 production. By building upon the current production base and increasing capacity, Positron will bring diversity and confidence to Sr-82 supply, thus providing further assurance that this technology will be a dependable, reliable modality for the nuclear cardiology community. The building blocks of Positron's vertical integration model for cardiac PET now includes Sr-82 API production and with this asset secured we've achieved a key milestone in our end-to-end solution's strategy."

About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiologyproviding an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES